EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Lecanemab approval in EU: what should we be ready for?– the EANM perspective

Igor Yakushev, Antoine Verger, Matthias Brendel, Diego Cecchin, Pablo Aguiar Fernandez, Francesco Fraioli, Timo Grimmer, Nelleke Tolboom, Tatjana Traub-Weidinger, Eric Guedj, Donatienne Van Weehaeghe

European Journal of Nuclear Medicine and Molecular Imaging · 2025-04 · 52 (5) · 1607-1610

DOI: 10.1007/s00259-025-07066-9 ↗

Kurz gefasst

Editorial in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 10.01.2025. Verfasst von Igor Yakushev und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Medicine, TUM University Hospital, Technical University of Munich, Klinikum rechts der Isar Ismaninger Str.…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität München.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

copy of the apolipoprotein E ε4 (ApoE ε4) gene, the primary genetic risk factor for sporadic AD. These individuals have a lower incidence of amyloid-related imaging abnormalities (ARIA), a side effect of anti-amyloid antibodies [3], relative

Autor:innen und Institutionen

  • Department of Nuclear Medicine, School of Medicine, TUM University Hospital, Technical University of Munich, Klinikum rechts der Isar Ismaninger Str. 22, 81675, Munich, Germany. igor.yakushev@tum.de.
  • Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Université de Lorraine, Nancy, France.
  • Department of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany.
  • Department of Medicine, Unit of Nuclear Medicine, University Hospital of Padova, Padova, Italy.
  • CIMUS, Universidade Santiago de Compostela & Nuclear Medicine Department, Univ. Hospital IDIS, Santiago de Compostela, Spain.
  • Institute of Nuclear Medicine, University College London, London, UK.

Förderung

  • Technische Universität München

Zitieren

APA

Yakushev, I., Verger, A., Brendel, M., Cecchin, D., Fernandez, P. A., Fraioli, F., Grimmer, T., Tolboom, N., Traub-Weidinger, T., Guedj, E., & Van Weehaeghe, D. (2025). Lecanemab approval in EU: what should we be ready for?– the EANM perspective. European Journal of Nuclear Medicine and Molecular Imaging, 52(5), 1607-1610. https://doi.org/10.1007/s00259-025-07066-9

Vancouver

Yakushev I, Verger A, Brendel M, Cecchin D, Fernandez PA, Fraioli F, et al. Lecanemab approval in EU: what should we be ready for?– the EANM perspective. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(5):1607-1610. doi:10.1007/s00259-025-07066-9

BibTeX
@article{Yakushev2025,
  author = {Yakushev, Igor and Verger, Antoine and Brendel, Matthias and Cecchin, Diego and Fernandez, Pablo Aguiar and Fraioli, Francesco and Grimmer, Timo and Tolboom, Nelleke and Traub-Weidinger, Tatjana and Guedj, Eric and Van Weehaeghe, Donatienne},
  title = {Lecanemab approval in EU: what should we be ready for?– the EANM perspective},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {5},
  pages = {1607--1610},
  doi = {10.1007/s00259-025-07066-9}
}
Kostenlos starten →